Evaluation of Postoperative Cognitive Function, Anxiety, Depression and Quality of Life in Patients With Unruptured Intracranial Aneurysms
8 maggio 2018 aggiornato da: Jun Wang, Xuanwu Hospital, Beijing
Evaluation of Postoperative Cognitive Function, Anxiety, Depression and Quality of Life in Patients With Unruptured Intracranial Aneurysms: a Multi-center Prospective Cohort Study
This prospective single-center cohort study aims to identify the incidence of cognitive dysfunction after unruptured aneurysm operation and explore the influencing factors.
The primary end point is the cognitive dysfunction at 6 months after operation.The features of cognitive function, mental status, neurological function recovery, and quality of life of patients with unruptured intracranial aneurysms at different time points would be analyzed.
Panoramica dello studio
Stato
Sconosciuto
Condizioni
Descrizione dettagliata
This main topics is to identify and screen the patients with unruptured aneurysm who likely to suffer from cognitive dysfunction.
All examinations were administered by a trained neuropsychologist.The assessment of cognitive function and mental state would be performed before operation and 6 months after operation, with the use of Montreal Cognitive Assessment Scale (MoCA) for the cognitive function, the Hamilton Anxiety Scale (HAMA) and the Hamilton Depression Scale (HDMA) tests for the mental state.
The Cognitive dysfunction at 6 months after operation would be the primary end point, and the underlying factors responsible for the declined cognitive function would be analyze.
The assessment of neurological function and quality of life would be performed before operation,3 months after operation and 6 months after operation, with the use of the Modified Rankin Scale(mRS) and the Functional Activities Questionnaire(FAQ) for the neurological function, the Richards-Campbell Sleep Questionnaire(RCSQ) and the 36-item short from health survey(SF-36) tests for the quality of life.
Tipo di studio
Osservativo
Iscrizione (Anticipato)
350
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
14 anni e precedenti (Bambino, Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Metodo di campionamento
Campione di probabilità
Popolazione di studio
the patients with unruptured intracranial aneurysms who treated in neurosurgery at Xuanwu Hospital
Descrizione
Inclusion Criteria:
- At least one imaging (CTA / MRI / DSA) study to confirm unruptured intracranial aneurysms for the patients who would undergo surgical treatment for the first time.;
- Patients who live independent with minimal care support, mRS score ≤3 points;
- Age > 14 years old;
- Han ethnicity, Right handed, can complete the test;
- Patient or family agrees to sign informed consent.
Exclusion Criteria:
- Other cerebrovascular diseases，such as ischemic stroke, arteriovenous malformation, etc;
- With an unexplained subarachnoid hemorrhage;
- History of Neurological disease surgery;
- Previous psychiatric and dementia history that cannot communicate with other people;
- Patients who refused to follow up.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: Coorte
- Prospettive temporali: Prospettiva
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
the Incidence of cognitive dysfunction at 6 months after operation
Lasso di tempo: the 6th month after operation of the patient inclusion in the study
|
The Montreal Cognitive Assessment Scale (MoCA) scale contains 8 cognitive domain,11 items and is suitable for assess cognitive function which including: Attention and concentration, executive function, memory, language, visual structure skills, abstract thinking, calculation and orientation.. 1 point for each correct answer.
No points if they make any errors.
The total score is 30 points.
For those who have been educated for 12 years or less and the total score of MoCA is less than 30, one point is added to the total MoCA score.
According to the results of MoCA assessment, Patients were divided into two groups: cognitive dysfunction group and cognitive function normal group.
MoCA score ≥26 points suggested normal cognitive function (CN).
|
the 6th month after operation of the patient inclusion in the study
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
the difference in the percentage of patients with HAMA score ≥14 before operation and 6 months after operation
Lasso di tempo: before operation and the 6th month after operation of the patient inclusion in the study
|
The Hamilton Anxiety Scale (HAMA) scale contains 14 items and is suitable for the adults with anxiety.
Each item is divided into 5 grades evaluated using 0 to 4 scores.
The total scores of HAMA scale can reflect patients' anxious condition to some extent.
The total scores of less than 7 is regarded as no anxiety, 7 or more possible anxiety, 14 or more definite anxiety, 21 or more marked anxiety, 29 or more severe anxiety.
In this study, Anxiety is defined as≥14 points.
|
before operation and the 6th month after operation of the patient inclusion in the study
|
|
the difference in the percentage of patients with HDMA score ≥14 before operation and 6 months after operation
Lasso di tempo: before operation and the 6th month after operation of the patient inclusion in the study
|
The Hamilton Depression Scale (HAMD) scale contains 24 items and is suitable for the adults with depression.
Each item is divided into 5 grades evaluated using 0 to 4 scores.
The total scores of the HAMD scale can reflect patients' depressive condition to some extent.
The total scores of less than 8 is regarded as no depression, 8 to 16 mild depression, 17 to 24 moderate depression, and more than 24 severe depression.
In this study, Depression is defined as≥14 points.
|
before operation and the 6th month after operation of the patient inclusion in the study
|
|
the tendency of mRS scores and the difference in the percentage of patients with mRS scores 0-3 and 4-6 points before operation, 3 months after operation, and 6 months after operation
Lasso di tempo: before operation ,the 3th month and the 6th month after operation of the patient inclusion in the study
|
The Modified Rankin Scale (mRS) is a valid and clinically relevant instrument that is used to assess recovery (death, disability, and dependence) after stroke and is a commonly used outcome measure in SAH studies.
The mRS ranges from 0 (no symptoms) to 6 (death).
Unfavourable outcome in survivors is defined as mRS 3-5.
|
before operation ,the 3th month and the 6th month after operation of the patient inclusion in the study
|
|
the tendency of SF-36 scores before operation, 3 months after operation, and 6 months after operation
Lasso di tempo: before operation ,the 3th month and the 6th month after operation of the patient inclusion in the study
|
36-item short form health survey(SF-36)
|
before operation ,the 3th month and the 6th month after operation of the patient inclusion in the study
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Cattedra di studio: Jun Wang, Master, Xuanwu Hospital, Beijing
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Anticipato)
1 maggio 2018
Completamento primario (Anticipato)
1 febbraio 2020
Completamento dello studio (Anticipato)
1 maggio 2020
Date di iscrizione allo studio
Primo inviato
3 aprile 2018
Primo inviato che soddisfa i criteri di controllo qualità
3 aprile 2018
Primo Inserito (Effettivo)
11 aprile 2018
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
9 maggio 2018
Ultimo aggiornamento inviato che soddisfa i criteri QC
8 maggio 2018
Ultimo verificato
1 maggio 2018
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- UIACGF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .